XM无法为美国居民提供服务。
C
C

Cigna


市场新闻

Humana slips as members in Medicare Advantage plans fall for 2025

BUZZ-Humana slips as members in Medicare Advantage plans fall for 2025 Updates ** Shares of health insurer Humana HUM.N fall as much as 23.7% to an over 4-year low of $213.31 ** Company says total members enrolled in its highly rated Medicare Advantage (MA) plans for people aged 65 years and above have reduced for 2025 ** HUM has about 1.6 mln, or 25%, of its members currently enrolled in plans rated 4 stars and above for 2025, down from 94% in 2024 ** Brokerage Evercore ISI says the news is pos
C

CVS surgery would provide little if any relief

RPT-BREAKINGVIEWS-CVS surgery would provide little if any relief The author is a Reuters Breakingviews columnist. The opinions expressed are his own. By Robert Cyran NEW YORK, Oct 1 (Reuters Breakingviews) - It’s easier to diagnose what ails CVS Health CVS.N than it is to prescribe a cure. Multiple profit warnings from the $78 billion healthcare conglomerate have raised doubts about its strategy.
A
C
W

CVS surgery would provide little if any relief

RPT-BREAKINGVIEWS-CVS surgery would provide little if any relief The author is a Reuters Breakingviews columnist. The opinions expressed are his own. By Robert Cyran NEW YORK, Oct 1 (Reuters Breakingviews) - It’s easier to diagnose what ails CVS Health CVS.N than it is to prescribe a cure. Multiple profit warnings from the $78 billion healthcare conglomerate have raised doubts about its strategy.
A
C
W

CVS surgery would provide little if any relief

BREAKINGVIEWS-CVS surgery would provide little if any relief The author is a Reuters Breakingviews columnist. The opinions expressed are his own. By Robert Cyran NEW YORK, Oct 1 (Reuters Breakingviews) - It’s easier to diagnose what ails CVS Health CVS.N than it is to prescribe a cure. Multiple profit warnings from the $78 billion healthcare conglomerate have raised doubts about its strategy.
A
C
W

CVS explores options including potential break-up, sources say

RPT-EXCLUSIVE-CVS explores options including potential break-up, sources say Adds background and details on CVS from paragraph 11 onwards By Anirban Sen NEW YORK, Sept 30 (Reuters) - CVS Health CVS.N is exploring options that could include a break-up of the company to separate its retail and insurance units, as the struggling healthcare services company looks to turn around its fortunes amid pressure from investors, people familiar with the matter told Reuters.
C

Health insurers unveil Medicare Advantage plans for 2025

UPDATE 2-Health insurers unveil Medicare Advantage plans for 2025 Adds details on UnitedHealth's plans in paragraphs 10 and 11 Oct 1 (Reuters) - Health insurers Cigna CI.N , CVS Health CVS.N , Humana HUM.N Centene CNC.N and UnitedHealth UNH.N on Tuesday released details on their government-backed health insurance plans for next year for people aged 65 and above.
C

CVS, Cigna unveil Medicare Advantage plans for 2025

CVS, Cigna unveil Medicare Advantage plans for 2025 Oct 1 (Reuters) - CVS Health CVS.N and Cigna CI.N on Tuesday released details on their government-backed health insurance plans for next year for people aged 65 and above , saying some members would pay $0 premium monthly for prescription drugs. The announcements come ahead of the beginning of enrollment for Medicare Advantage plans on October 15, which will continue through December 7. Medicare Advantage plans are offered by private insurers w
C

CVS explores options including potential break-up, sources say

EXCLUSIVE-CVS explores options including potential break-up, sources say Adds background and details on CVS from paragraph 11 onwards By Anirban Sen NEW YORK, Sept 30 (Reuters) - CVS Health CVS.N is exploring options that could include a break-up of the company to separate its retail and insurance units, as the struggling healthcare services company looks to turn around its fortunes amid pressure from investors, people familiar with the matter told Reuters.
C

US Senator Sanders says middlemen won't punish Novo if it cuts weight-loss drug prices

UPDATE 4-US Senator Sanders says middlemen won't punish Novo if it cuts weight-loss drug prices Adds Lilly background in paragraph 7, CEO comment on working with PBMs, paragraph 11 By Ahmed Aboulenein and Patrick Wingrove WASHINGTON, Sept 24 (Reuters) - U.S. Senator Bernie Sanders said on Tuesday he had commitments from the nation's top pharmacy benefit managers that they would expand coverage of Novo Nordisk's NOVOb.CO popular diabetes and weight-loss medicines if the company lowered the list p
C

What to Watch in the Day Ahead - Tuesday, September 24

What to Watch in the Day Ahead - Tuesday, September 24 The Day Ahead is an email and PDF publication that includes the day's major stories and events, analyses and other features. To receive The Day Ahead, Eikon users can register at DAY/US . Thomson One users can register at RT/DAY/US. All times in ET/GMT Federal Reserve Board Governor Michelle Bowman is slated to speak on the economic outlook and monetary policy before the Kentucky Bankers Association Annual Convention in Virginia.
C

Why are US pharmacy benefit managers under fire?

EXPLAINER-Why are US pharmacy benefit managers under fire? By Ahmed Aboulenein WASHINGTON, Sept 20 (Reuters) - The U.S. Federal Trade Commission said on Friday it was suing the country's three largest pharmacy benefit managers, accusing them of abusing their power and rigging the pharmaceutical supply chain to artificially inflate the cost of insulin.
C

US FTC sues drug 'gatekeepers' over high insulin prices

UPDATE 3-US FTC sues drug 'gatekeepers' over high insulin prices Adds outside comment in paragraphs 6-7, drug company comment in paragraph 18, investor comment in paragraphs 21-22 By Jody Godoy and Ahmed Aboulenein Sept 20 (Reuters) - The U.S. Federal Trade Commission sued the country's three largest pharmacy benefit managers on Friday, accusing them of steering diabetes patients towards higher priced insulin in order to reap millions of dollars in rebates from pharmaceutical companies.
C
S

US FTC sues drug 'gatekeepers' over high insulin prices

US FTC sues drug 'gatekeepers' over high insulin prices By Jody Godoy and Ahmed Aboulenein Sept 20 (Reuters) - The U.S. Federal Trade Commission sued the country's three largest pharmacy benefit managers on Friday, accusing them of steering diabetic patients towards higher priced insulin in order to reap millions of dollars in rebates from pharmaceutical companies.
C
S

U.S. STOCKS AppLovin, Regal Rexnord, Talkspace

BUZZ-U.S. STOCKS ON THE MOVE- AppLovin, Regal Rexnord, Talkspace Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main stock indexes rose on Tuesday, with the S&P 500 hitting an intraday record high ahead of a crucial Federal Reserve interest-rate decision, after fresh economic data allayed worries of a sharp slowdown in the U.S.
A
C
I
M
N
S
U
U
D

Express Scripts sues FTC over drug pricing report, court documents show

UPDATE 2-Express Scripts sues FTC over drug pricing report Adds detail from the complaint and FTC comment in paragraphs 4-8, updates headline, byline and dateline By Jody Godoy NEW YORK, Sept 17 (Reuters) - Pharmacy benefit manager Express Scripts sued the U.S. Federal Trade Commission on Tuesday over the regulator's recent drug pricing report , calling the report's conclusion that the prescription middlemen raise drug costs defamatory.
C

Express Scripts sues FTC over drug pricing report, court documents show

Express Scripts sues FTC over drug pricing report, court documents show WASHINGTON, Sept 17 (Reuters) - Pharmacy benefit manager Express Scripts has sued the U.S. Federal Trade Commission over the regulator's recent drug pricing report , asking a court to force the agency to withdraw its findings, according to court documents filed on Tuesday. Repo
C

U.S. Aerovironment, Insulet, Viasat

U.S. RESEARCH ROUNDUP- Aerovironment, Insulet, Viasat Sept 17 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Aerovironment, Insulet and Viasat, on Tuesday. HIGHLIGHTS * Aerovironment Inc AVAV.O : Raymond James cuts to market perform from outperform * Frontier Communications Parent Inc FYBR.O : JP Morgan cuts to neutral from overweight * Insulet Corp PODD.O : Piper Sandler raises target price to $285 from $230 * Relm
B
C
C
E
I
D

US employers expect nearly 6% spike in health insurance costs in 2025, Mercer says

US employers expect nearly 6% spike in health insurance costs in 2025, Mercer says By Amina Niasse NEW YORK, Sept 12 (Reuters) - U.S. employers expect health insurance costs to rise an average 5.8% in 2025, largely due to increased cost of medical services as well as higher use, according to a survey released by consulting firm Mercer on Thursday.
C

Cigna Healthcare Makes Virtual Care Even Easier And More Convenient With New E-Treatment Option From MDLIVE

BRIEF-Cigna Healthcare Makes Virtual Care Even Easier And More Convenient With New E-Treatment Option From MDLIVE Sept 12 (Reuters) - Cigna Group CI.N : CIGNA HEALTHCARE MAKES VIRTUAL CARE EVEN EASIER AND MORE CONVENIENT WITH NEW E-TREATMENT OPTION FROM MDLIVE Source text for Eikon: ID:nPn2lrgZga Further company coverage: CI.N
C

UnitedHealth to remove AbbVie's Humira from some US drug reimbursement lists next year

UnitedHealth to remove AbbVie's Humira from some US drug reimbursement lists next year By Patrick Wingrove Sept 10 (Reuters) - UnitedHealth Group UNH.N said on Tuesday it will remove AbbVie’s ABBV.N blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement as of Jan. 1, 2025, and recommend less expensive biosimilar versions of the medicine instead.
A
C
P
T



商品详情

热门商品

免责声明: XM Group仅提供在线交易平台的执行服务和访问权限,并允许个人查看和/或使用网站或网站所提供的内容,但无意进行任何更改或扩展,也不会更改或扩展其服务和访问权限。所有访问和使用权限,将受下列条款与条例约束:(i) 条款与条例;(ii) 风险提示;以及(iii) 完整免责声明。请注意,网站所提供的所有讯息,仅限一般资讯用途。此外,XM所有在线交易平台的内容并不构成,也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。

所有在线交易平台所发布的资料,仅适用于教育/资讯类用途,不包含也不应被视为用于金融、投资税或交易相关咨询和建议,或是交易价格纪录,或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。

本网站上由XM和第三方供应商所提供的所有内容,包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接,皆保持不变,并作为一般市场评论所提供,而非投资性建议。所有在线交易平台所发布的资料,仅适用于教育/资讯类用途,不包含也不应被视为适用于金融、投资税或交易相关咨询和建议,或是交易价格纪录,或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解,XM非独立投资研究提示和风险提示相关资讯,更多详情请点击 这里

风险提示: 您的资金存在风险。杠杆商品并不适合所有客户。请详细阅读我们的风险声明